Dividends & Buybacks ·
Apimeds Pharmaceuticals US, Inc. filed a Certificate of Amendment to effect a one-for-ten (1-for-10) reverse stock…
APUSApimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. filed a Certificate of Amendment to effect a one-for-ten (1-for-10) reverse stock split of its common stock, effective July 24, 2026. The company reduced the par value from $0.01 to $0.001 per share. Outstanding shares decreased from 15,091,180 to 1,509,118, with an additional 33,506 shares issued to accommodate fractional share rounding. The split did not alter the authorized share count of 100 million common or 10 million preferred shares. Equity awards and warrants were proportionately adjusted. Apimeds Pharmaceuticals US, Inc. operates in the pharmaceutical industry, focusing on drug development.